Indeterminate Lesions clinical trials at UCLA
1 in progress, 0 open to eligible people
Showing trials for
Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Sorry, not currently recruiting here
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Indeterminate Lesions research studies include Tara A. McCannel, MD, PhD.
Last updated: